| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF00966691 |
| P698 | PubMed publication ID | 8255359 |
| P50 | author | Fulvio Marzatico | Q69365508 |
| P2093 | author name string | G Benzi | |
| M Taborelli | |||
| C Café | |||
| P2860 | cites work | A fluorometric method for determination of oxidized and reduced glutathione in tissues | Q67805316 |
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and free radicals in vitro | Q69845306 | ||
| Neurological consequence of industrial exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine | Q69858010 | ||
| A stereotaxic atlas of the brain of the cynomolgus monkey (Macaca fascicularis) | Q70325126 | ||
| Neurotoxicity of the meperidine analogue N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurons in the mouse | Q71002559 | ||
| Cerebral and cerebellar metabolic changes induced by drugs during the recovery period after profound hypoglycemia | Q71297186 | ||
| Regional distribution of catalase in the adult rat brain | Q71482413 | ||
| Mitochondrial formation of OH Radicals by an ubisemiquinone-dependent reaction an alternative pathway to the iron-catalysed Haber-Weiss cycle | Q72940163 | ||
| Protein measurement with the Folin phenol reagent | Q20900776 | ||
| Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis | Q22242250 | ||
| Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey | Q28270776 | ||
| Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases | Q28306057 | ||
| Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction | Q29616762 | ||
| A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine | Q37343442 | ||
| Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones | Q39615110 | ||
| Biochemical fundamentals of Parkinson's disease | Q39631927 | ||
| Catecholamine toxicity: a proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson's disease | Q41582319 | ||
| Parkinson's disease: a disorder due to nigral glutathione deficiency? | Q41628096 | ||
| Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease | Q44808814 | ||
| Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients | Q48331251 | ||
| Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium | Q48349404 | ||
| Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant pretreatment | Q48386729 | ||
| The mitochondrial electron transfer alteration as a factor involved in the brain aging | Q48490365 | ||
| Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects | Q48535241 | ||
| Glutathione peroxidase levels in brain | Q48560707 | ||
| Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism | Q48614154 | ||
| Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice | Q48655550 | ||
| Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase | Q48681443 | ||
| The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence | Q48839624 | ||
| Quantitative analysis of glutathione in human brain tumors | Q49050061 | ||
| Age-related effect induced by oxidative stress on the cerebral glutathione system | Q60722277 | ||
| Changes induced by aging and drug treatment on cerebral enzymatic antioxidant system | Q60722292 | ||
| Influence of aging and drug treatment on the cerebral glutathione system | Q60722302 | ||
| P433 | issue | 10 | |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 1101-1106 | |
| P577 | publication date | 1993-10-01 | |
| P1433 | published in | Neurochemical Research | Q15716728 |
| P1476 | title | Experimental Parkinson's disease in monkeys. Effect of ergot alkaloid derivative on lipid peroxidation in different brain areas | |
| P478 | volume | 18 |
| Q59136731 | Arbutin attenuates behavioral impairment and oxidative stress in an animal model of Parkinson's disease |
| Q48729861 | Bromocriptine is a strong inhibitor of brain nitric oxide synthase: possible consequences for the origin of its therapeutic effects |
| Q42505353 | Contrast optimization of Macaca mulatta basal ganglia in magnetic resonance images at 4.7 Tesla |
| Q48561566 | MPTP produces differential oxidative stress and antioxidative responses in the nigrostriatal and mesolimbic dopaminergic pathways |
| Q92463785 | Matrix augmentation as an efficient method for resolving interaction of bromocriptine with human serum albumin: trouble shooting and simultaneous resolution |
| Q31923969 | SKF-38393, a dopamine receptor agonist, attenuates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity |
| Q28540349 | Salvianolic acid B attenuates toxin-induced neuronal damage via Nrf2-dependent glial cells-mediated protective activity in Parkinson's disease models |
| Q48111607 | Striatal metabolism of hexanal, a lipid peroxidation product, in the rat. |
Search more.